Lycia Therapeutics Inc. (LYCA) vs Novavax, Inc. (NVAX)

Lycia Therapeutics Inc. LYCA 30.50 +5.90%
Novavax, Inc. NVAX 10.78 +10.22%

Lycia Therapeutics Inc. and Novavax, Inc. are both Biotechnology companies. Lycia Therapeutics Inc. and Novavax, Inc. are of similar size ($1.7B and $1.6B).

Metric	LYCA	NVAX	Biotechnology median
P/E	—	n/m	10.60
P/S	—	4.31	9.40
P/B	—	n/m	2.13
Price to free cash flow	—	n/m	25.18
EV/EBITDA	—	n/m	0.66
EV/Sales	—	3.28	9.02
Earnings yield	—	(4.28%)	(32.88%)
Free cash flow yield	—	(13.87%)	(23.13%)

Metric	LYCA	NVAX	Biotechnology median
Gross margin	—	78.01%	68.51%
Operating margin	—	(21.23%)	0.00%
Net margin	—	(18.64%)	0.00%
Free cash flow margin	—	(58.05%)	0.00%
Return on equity	—	41.08%	(51.96%)
Return on assets	—	(7.42%)	(46.06%)
Return on invested capital	—	0.00%	0.00%

Metric	LYCA	NVAX	Biotechnology median
Revenue growth (TTM)	—	(61.33%)	6.76%
EPS growth (last fiscal year)	—	309.76%	29.88%
Revenue growth, 5-year CAGR	—	18.76%	9.75%
Net income growth, 5-year CAGR	—	0.00%	0.00%

Metric	LYCA	NVAX	Biotechnology median
Debt to equity	—	0.00	0.00
Current ratio	—	2.15	4.97
Net debt to EBITDA	—	(1.04)	1.01

Metric	LYCA	NVAX	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	LYCA	NVAX	Biotechnology median
Market cap	1.66b	1.61b	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack